Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

PolyNovo achieves 26% revenue growth and shares rise after strong half-year report

PolyNovo reports group revenue of AUD 68.2m for H1 2026 (+26%) and adjusted EBITDA of AUD 4.7m (+82%), driven by strong growth in the US (75.8% of revenue) and 95 new hospital customers. The share price rose 5.72% to AUD 1.005; gross margin was temporarily pushed down to 88.8% by manufacturing optimization measures. The company plans to complete a new production facility by July 2026 and is preparing a PMA submission for a product to treat full-thickness burns. » Mais em de.investing.com
Polynovo shares jump sharply after CMS proposal for skin substitute reimbursement

Polynovo shares surged after a US CMS proposal for a uniform flat reimbursement of $806 per square inch for skin substitutes. Polynovo said its NovoSorb products should remain profitable under the new model; interim CEO Robyn Elliott sees significant growth potential in the outpatient market. A final decision is expected in November, with implementation planned for January 2026. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2022, Polynovo já distribuiu € 0,14 em dividendos. A última distribuição ocorreu em maio de 2022.

Dados financeiros da empresa

No último trimestre, Polynovo registou receitas de € 44,45 mi e um ganho líquido de € 4,44 mi

(EUR)	junho de 2026	YoY
Receitas	44,45 mi	-
Ganho bruto	15,44 mi	-
Ganho líquido	4,44 mi	-
EBITDA	3,94 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 450,9 mi
Número de ações	690,84 mi
Máximo/mínimo de 52 semanas	€ 0,88 - € 0,48
Dividendos	Não
Beta	1,38
PER (PE Ratio)	92,45
PEG (PEG Ratio)	-2,08
P/VC (PB Ratio)	7,46
P/V (PS Ratio)	4,71

Perfil da empresa

Polynovo Limited entwickelt Medizinprodukte in den Vereinigten Staaten, Australien, Neuseeland, dem Vereinigten Königreich, Irland, Singapur und international. Das Unternehmen bietet die biologisch abbaubare temporäre Matrix NovoSorb an, die in einer vollständig debridierten, sauberen chirurgischen Wunde verwendet wird, um die Wunde physiologisch zu schließen. Darüber hinaus entwickelt es Syntrel Hernienvorrichtungen für die Hernienreparatur, NovoSorb Dermal Beta Cell Implant, das Pankreasinseln in der Haut beherbergt, und NovoSorb Drug Elution Depots. Das Unternehmen war früher unter dem Namen Calzada Limited bekannt und änderte im November 2014 seinen Namen in Polynovo Limited. Polynovo Limited wurde 1998 gegründet und hat seinen Hauptsitz in Port Melbourne, Australien.